HCA Healthcare, Inc.

Valuation Analysis

About the Company

HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory ther

HCA Healthcare, Inc. Stock at a Glance

HCA Healthcare, Inc. (HCA) is currently trading at $387.18 with a market capitalization of $85.9B. The trailing P/E ratio stands at 13.33x, with a forward P/E of 11.69x. The 52-week range spans from $330.00 to $556.52; the current price is 30.4% below the yearly high. Year-over-year revenue growth stands at +4.3%. The net profit margin stands at 8.89%.

💰 Dividend

HCA Healthcare, Inc. pays an annual dividend of $3.12 per share, representing a yield of 0.81%. The payout ratio stands at 10.13%.

📊 Analyst Rating

21 analysts rate HCA Healthcare, Inc. (HCA) on consensus: Buy. The average price target is $503.57, implying +30.06% from the current price. Analyst price targets range from $396.00 to $635.00.

HCA Healthcare, Inc.: The Investment Case in Detail

HCA Healthcare, Inc. (HCA) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 30.06% upside from current levels — analyst sentiment is firmly constructive. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 4.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Valuation in Context

The PEG ratio at 1.17 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 8.87x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 11.69x is meaningfully below the trailing 13.33x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 30.06% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to market-like volatility.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy HCA Healthcare, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.